FeesSafety
Pluang+

iBio shows promising preclinical data for obesity antibody IBIO-610 and amylin program at major conferences

Market News
16 Nov 2026, 23:30 WIB
GlobeNewsWire
View Source
Bullish
iBio shows promising preclinical data for obesity antibody IBIO-610 and amylin program at major conferences

iBio, Inc. presented new preclinical data for its obesity and cardiometabolic drug candidates, including IBIO-610, an Activin E antibody, which showed sustained suppression of Activin E and a 2.3% reduction in body weight in obese non-human primates over 28 weeks. The data also indicated significant fat reduction while maintaining lean mass. Additionally, iBio's amylin program demonstrated selective activation of amylin receptors and reduced food intake in rats, supporting further development of long-acting therapies. These findings highlight iBio's AI-driven antibody platform's potential to create targeted treatments for weight management and cardiometabolic health, with upcoming studies planned to advance these candidates.

iBio's new preclinical data on obesity and cardiometabolic drug candidates is presented here as context for readers. For those following the Health sector, Pluang's market snapshot as of Nov 17, 2026 04:12 WIB shows 29 of 150 US health stocks rose while 121 fell. Notably, RXRX traded at USD 2.91 with a 1-day change of -8.63% and 100% buy orders, contrasting with AMLX at USD 27.76 down 8.35% with 100% sell orders, and NUWE at USD 4.51 down 7.96%.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App